News
“In the last several weeks, our publication on the value of 3CL protease inhibitors supplementation with Tollovid in the Long COVID setting, combined with a plethora of academic publications ...
NLC-001 is an orally administered proprietary blend of plant extracts that includes a powerful potential 3CL protease inhibitor that could help support and maintain healthy immune function.
Remdesivir is an RNA-dependent RNA polymerase (RdRp) inhibitor that has received ... study acts on the SARS-CoV-2 main protease or 3C-like protease (3CL protease or 3CLpro). This is required ...
its coronavirus 3CL protease inhibitor (also known as the main coronavirus protease, or Mpro) specifically designed as a once-daily, oral treatment for COVID-19. "Despite the broad availability of ...
The term “protease inhibitor” refers to a class of medications rather than to a single medication. Specifically, they are antiviral drugs. But unlike the many, more common antiviral drugs that ...
US CDC drops COVID-19 vaccine recommendation for children and pregnant people Amgen unveils its KRas inhibitor in human ... The compound targets the 3CL protease, an enzyme that coronaviruses ...
All three groups will be allowed to continue taking their standard of care medications while on study, with the exception of other 3CL protease inhibitors. 3CL Pharma intends to initiate this ...
3CL protease inhibitors are targeted as desirable candidates for development of antiviral therapies against SARS-CoV-2 (the virus that causes COVID-19). The primary endpoints of the Clinical Trial ...
Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. The candidate is intended to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results